SUGARNSALT, NCT06217302: Sotagliflozin to Slow Kidney Function Decline in Persons with Type 1 Diabetes and Diabetic Kidney Disease |
|
|
| Recruiting | 3 | 150 | Canada, US | Sotagliflozin, INPEFA, Placebo | Alessandro Doria, Canadian Institutes of Health Research (CIHR), The Kidney Foundation of Canada, The Cleveland Clinic, University of Michigan, University of Colorado, Denver, Northwestern University, Washington University School of Medicine, State University of New York - Upstate Medical University, Providence Medical Research Center, Stanford University, Montefiore Medical Center, University of Toronto, University Health Network, Toronto, University of Calgary, University of Alberta, University of British Columbia, Institut de Recherches Cliniques de Montreal, LMC Diabetes & Endocrinology Ltd., Joslin Diabetes Center, Lexicon Pharmaceuticals, DexCom, Inc., University of Washington, Breakthrough T1D | Diabetic Nephropathies, Kidney Failure, Chronic, Diabetes Mellitus Type 1, Heart Failure | 12/28 | 05/29 | | |
ASPIRE, NCT06072326: Ambrisentan Sotagliflozin and Prevention of Renal Injury; a Randomized Evaluation |
|
|
| Not yet recruiting | 2 | 36 | Europe, Canada, US | Sotagliflozin, Ambrisentan, Ambrisentan and Sotagliflozin | University Medical Center Groningen, Juvenile Diabetes Research Foundation, Lexicon Pharmaceuticals | Type 1 Diabetes Mellitus With Diabetic Nephropathy | 03/25 | 03/25 | | |
NCT05936151: A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes |
|
|
| Recruiting | 2 | 120 | Europe, Canada, US | Retatrutide, LY3437943, Placebo | Eli Lilly and Company | Overweight or Obesity, CKD, Type 2 Diabetes | 11/25 | 11/25 | | |
| Recruiting | 2 | 140 | Europe, Canada, US, RoW | Tirzepatide, Placebo | Eli Lilly and Company, Eli Lilly and Company | Overweight, Obesity, Chronic Kidney Disease, Type 2 Diabetes, T2D | 01/26 | 02/26 | | |
